$MEIP
MEI Pharma, Inc.

2021 Q2 Form 10-K Financial Statement

#000095017021001655 Filed on September 02, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2021 2020 Q2
Revenue $19.38M $25.54M $25.50M
YoY Change -24.02% -11.68% 2158.99%
Cost Of Revenue $0.00 $1.408M $480.0K
YoY Change -100.0% -47.29% -56.36%
Gross Profit $19.38M $24.13M $25.02M
YoY Change -22.55% -8.06% 83300.0%
Gross Profit Margin 100.0% 94.49% 98.1%
Selling, General & Admin $6.634M $24.41M $4.530M
YoY Change 46.45% 46.02% 21.12%
% of Gross Profit 34.24% 101.19% 18.11%
Research & Development $16.29M $69.40M $7.860M
YoY Change 107.3% 103.72% -2.12%
% of Gross Profit 84.09% 287.64% 31.41%
Depreciation & Amortization $65.00K $285.0K $20.00K
YoY Change 225.0% 161.47% -33.33%
% of Gross Profit 0.34% 1.18% 0.08%
Operating Expenses $22.93M $69.40M $12.39M
YoY Change 85.05% 103.72% 5.18%
Operating Profit -$3.551M -$69.69M $12.63M
YoY Change -128.12% 183.96% -207.49%
Interest Expense $7.100M $18.63M -$31.11M
YoY Change -122.82% -186.74% -310.2%
% of Operating Profit -246.32%
Other Income/Expense, Net $4.000K $486.0K $0.00
YoY Change -100.0%
Pretax Income $3.553M -$50.57M -$18.48M
YoY Change -119.23% 9.89% -705.9%
Income Tax $8.000K $8.000K $0.00
% Of Pretax Income 0.23%
Net Earnings $3.545M -$50.58M -$18.48M
YoY Change -119.19% 9.91% -705.37%
Net Earnings / Revenue 18.29% -198.06% -72.44%
Basic Earnings Per Share -$0.45 -$0.17
Diluted Earnings Per Share $31.49K -$0.68 -$0.17
COMMON SHARES
Basic Shares Outstanding 112.6M 112.5M 106.0M
Diluted Shares Outstanding 114.5M

Balance Sheet

Concept 2021 Q2 2021 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $153.4M $153.4M $182.6M
YoY Change -15.98% -15.98% 145.1%
Cash & Equivalents $8.543M $8.543M $12.33M
Short-Term Investments $144.9M $144.9M $170.3M
Other Short-Term Assets $3.809M $3.809M $5.000M
YoY Change -23.82% -23.82% 108.33%
Inventory
Prepaid Expenses
Receivables $7.582M $600.0K
Other Receivables $0.00 $0.00 $20.40M
Total Short-Term Assets $164.8M $164.8M $208.6M
YoY Change -21.01% -20.99% 153.83%
LONG-TERM ASSETS
Property, Plant & Equipment $1.507M $9.281M $1.084M
YoY Change 39.02% 743.73% 431.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $9.281M $9.281M $1.084M
YoY Change 756.18% 743.73% 133.12%
TOTAL ASSETS
Total Short-Term Assets $164.8M $164.8M $208.6M
Total Long-Term Assets $9.281M $9.281M $1.084M
Total Assets $174.1M $174.1M $209.7M
YoY Change -16.99% -16.98% 153.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.355M $6.355M $2.437M
YoY Change 160.77% 164.79% -49.09%
Accrued Expenses $8.402M $9.330M $6.090M
YoY Change 37.96% 52.95% 33.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.21M $20.21M $23.30M
YoY Change -13.27% -13.26% 62.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $104.4M $104.4M $108.2M
YoY Change -3.49% -3.49% 430.39%
Total Long-Term Liabilities $104.4M $104.4M $108.2M
YoY Change -3.49% -3.49% 430.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.21M $20.21M $23.30M
Total Long-Term Liabilities $104.4M $104.4M $108.2M
Total Liabilities $124.6M $124.6M $131.5M
YoY Change -5.23% -5.22% 278.63%
SHAREHOLDERS EQUITY
Retained Earnings -$319.7M -$277.2M
YoY Change 15.32% 19.9%
Common Stock $369.2M $355.5M
YoY Change 3.86% 27.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.47M $49.47M $77.06M
YoY Change
Total Liabilities & Shareholders Equity $174.1M $174.1M $209.7M
YoY Change -16.99% -16.98% 153.71%

Cashflow Statement

Concept 2021 Q2 2021 2020 Q2
OPERATING ACTIVITIES
Net Income $3.545M -$50.58M -$18.48M
YoY Change -119.19% 9.91% -705.37%
Depreciation, Depletion And Amortization $65.00K $285.0K $20.00K
YoY Change 225.0% 161.47% -33.33%
Cash From Operating Activities -$11.25M -$31.96M $69.11M
YoY Change -116.28% -193.3% -957.44%
INVESTING ACTIVITIES
Capital Expenditures -$8.000K $708.0K -$100.0K
YoY Change -92.0% -20.81% 900.0%
Acquisitions
YoY Change
Other Investing Activities $9.996M $25.42M -$84.94M
YoY Change -111.77% -124.11% -951.96%
Cash From Investing Activities $9.988M $24.71M -$85.04M
YoY Change -111.75% -123.24% -953.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 68.00K 3.468M 20.83M
YoY Change -99.67% -95.36% 7339.29%
NET CHANGE
Cash From Operating Activities -11.25M -31.96M 69.11M
Cash From Investing Activities 9.988M 24.71M -85.04M
Cash From Financing Activities 68.00K 3.468M 20.83M
Net Change In Cash -1.198M -3.788M 4.900M
YoY Change -124.45% -238.2% 124.77%
FREE CASH FLOW
Cash From Operating Activities -$11.25M -$31.96M $69.11M
Capital Expenditures -$8.000K $708.0K -$100.0K
Free Cash Flow -$11.25M -$32.67M $69.21M
YoY Change -116.25% -197.93% -959.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2028-03-31
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001262104
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
000-50484
CY2021 dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
51-0407811
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
11455 El Camino Real
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
CY2021 dei City Area Code
CityAreaCode
858
CY2021 dei Local Phone Number
LocalPhoneNumber
369-7100
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.00000002 par value
CY2021 dei Trading Symbol
TradingSymbol
MEIP
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Public Float
EntityPublicFloat
300800000
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
112678498
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8543000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12331000
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
144883000
CY2020Q2 us-gaap Short Term Investments
ShortTermInvestments
170299000
CY2021Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
153426000
CY2020Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
182630000
CY2021Q2 meip Receivable For Foreign Tax Withholding
ReceivableForForeignTaxWithholding
0
CY2020Q2 meip Receivable For Foreign Tax Withholding
ReceivableForForeignTaxWithholding
20420000
CY2021Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7582000
CY2020Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
2858000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3809000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2736000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
164817000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
208644000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7774000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1507000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1084000
CY2021Q2 us-gaap Assets
Assets
174098000
CY2020Q2 us-gaap Assets
Assets
209728000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6355000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2437000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8402000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6090000
CY2021Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14609000
CY2020Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14777000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
928000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
30294000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
23304000
CY2021Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
72717000
CY2020Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
67723000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7370000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
22355000
CY2020Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
40483000
CY2021Q2 us-gaap Liabilities
Liabilities
132736000
CY2020Q2 us-gaap Liabilities
Liabilities
131510000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
112615000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
112615000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
111514000
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
111514000
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
369171000
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
355452000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-327809000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-277234000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
41362000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
78218000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
174098000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
209728000
CY2021 us-gaap Revenues
Revenues
25535000
CY2020 us-gaap Revenues
Revenues
28913000
CY2019 us-gaap Revenues
Revenues
4915000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1408000
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2671000
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4263000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69398000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34065000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32300000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24414000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16717000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14597000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
95220000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
53453000
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
51160000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-69685000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-24540000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-46245000
CY2021 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
18122000
CY2020 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-22870000
CY2019 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
27632000
CY2021 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
510000
CY2020 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1395000
CY2019 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1795000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
486000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-50575000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-46016000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-16819000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50575000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-46016000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16819000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-77969000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-46016000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-54613000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112527000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91080000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71139000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114481000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91080000
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72385000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
50459000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-16819000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5444000
CY2019 meip Stockissuedduringperiodvaluestockwarrantsexercised
Stockissuedduringperiodvaluestockwarrantsexercised
2186000
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-324000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
422000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6562000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
47930000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-46016000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
69231000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
272000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6801000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
78218000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-50575000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3136000
CY2021 meip Stockissuedduringperiodvaluestockwarrantsexercised
Stockissuedduringperiodvaluestockwarrantsexercised
6000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
332000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10245000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
41362000
CY2021 us-gaap Profit Loss
ProfitLoss
-50575000
CY2020 us-gaap Profit Loss
ProfitLoss
-46016000
CY2019 us-gaap Profit Loss
ProfitLoss
-16819000
CY2021 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
18122000
CY2020 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-22870000
CY2019 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
27632000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
10245000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
6801000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
6562000
CY2020 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
227000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
285000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
109000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
80000
CY2021 meip Increase Or Decrease In Receivable For Foreign Tax Withholding
IncreaseOrDecreaseInReceivableForForeignTaxWithholding
20420000
CY2020 meip Increase Or Decrease In Receivable For Foreign Tax Withholding
IncreaseOrDecreaseInReceivableForForeignTaxWithholding
-20420000
CY2021 us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
4724000
CY2020 us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
2347000
CY2019 us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
199000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1073000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
812000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
650000
CY2021 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
3918000
CY2020 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2350000
CY2019 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1144000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2312000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1470000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1105000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4826000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
74726000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
6986000
CY2021 meip Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
524000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31964000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
34258000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29423000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
708000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
894000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
217000
CY2021 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
420153000
CY2020 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
190279000
CY2019 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
64655000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
445569000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
84879000
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
89190000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24708000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-106294000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24318000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
332000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
272000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
372000
CY2021 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
3136000
CY2020 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
69231000
CY2019 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
220000
CY2020 meip Proceeds From Previously Issued Common Stock
ProceedsFromPreviouslyIssuedCommonStock
5274000
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1118000
CY2019 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
324000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3468000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
74777000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1386000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3788000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2741000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3719000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12331000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9590000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13309000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8543000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12331000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9590000
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-8000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-1000
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-1000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8689000
CY2021 meip Warrants Issued Pursuant To Cashless Exercise
WarrantsIssuedPursuantToCashlessExercise
6000
CY2019Q2 meip Non Cash Proceeds From Sale Of Common Stock Receivable
NonCashProceedsFromSaleOfCommonStockReceivable
5224000
CY2019Q2 meip Non Cash Proceeds From Stock Option Exercised Receivable
NonCashProceedsFromStockOptionExercisedReceivable
50000
CY2019Q2 meip Change In Fair Value Of Warrants Exercised
ChangeInFairValueOfWarrantsExercised
1068000
CY2021 meip Number Of Clinical Stage Candidates
NumberOfClinicalStageCandidates
4
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates.</span></p>
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-327800000
CY2021Q2 meip Cash And Cash Equivalentsshort Term Investments And Common Stock Proceeds Receivable
CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable
153400000
CY2021 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Reclassifications</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain reclassifications have been made to the prior year financial statements to conform to the current year financial statement presentation of contract assets. These changes did not impact previously reported net loss, loss per share, stockholders’ equity, total assets or cash flows.</span></p>
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
144900000
CY2020Q2 us-gaap Short Term Investments
ShortTermInvestments
170300000
CY2020 meip Revenue Performance Obligation Amount
RevenuePerformanceObligationAmount
27500000
CY2019 meip Revenue Performance Obligation Amount
RevenuePerformanceObligationAmount
2600000
CY2021 us-gaap Revenues
Revenues
25535000
CY2020 us-gaap Revenues
Revenues
28913000
CY2019 us-gaap Revenues
Revenues
4915000
CY2021 us-gaap Revenues
Revenues
25535000
CY2020 us-gaap Revenues
Revenues
28913000
CY2019 us-gaap Revenues
Revenues
4915000
CY2021 meip Revenue Performance Obligation Amount
RevenuePerformanceObligationAmount
25100000
CY2020Q2 meip Accounts Receivable Net Beginning Balance
AccountsReceivableNetBeginningBalance
83000
CY2019Q2 meip Accounts Receivable Net Beginning Balance
AccountsReceivableNetBeginningBalance
0
CY2021 meip Receivables Amounts Billed
ReceivablesAmountsBilled
25682000
CY2020 meip Receivables Amounts Billed
ReceivablesAmountsBilled
1292000
CY2021 meip Receivables Payments Received
ReceivablesPaymentsReceived
-25765000
CY2020 meip Receivables Payments Received
ReceivablesPaymentsReceived
-1209000
CY2021Q2 meip Accounts Receivable Net Ending Balance
AccountsReceivableNetEndingBalance
0
CY2020Q2 meip Accounts Receivable Net Ending Balance
AccountsReceivableNetEndingBalance
83000
CY2020Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
2858000
CY2019Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
511000
CY2021 meip Contract Assets Billable Amounts
ContractAssetsBillableAmounts
30406000
CY2020 meip Contract Assets Billable Amounts
ContractAssetsBillableAmounts
3639000
CY2021 meip Contract Assets Amounts Billed
ContractAssetsAmountsBilled
-25682000
CY2020 meip Contract Assets Amounts Billed
ContractAssetsAmountsBilled
-1292000
CY2021Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7582000
CY2020Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
2858000
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
17955000
CY2019Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
7774000
CY2021 meip Increase Decrease Customer Liabilities
IncreaseDecreaseCustomerLiabilities
4826000
CY2020 meip Increase Decrease Customer Liabilities
IncreaseDecreaseCustomerLiabilities
10181000
CY2021Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
22781000
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
17955000
CY2021 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
87300000
CY2021 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Other Information
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleOtherInformation
An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
CY2021Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2020 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2019 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50575000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-46016000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16819000
CY2021 meip Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
-27394000
CY2019 meip Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
-37794000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-77969000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-46016000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-54613000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112527000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91080000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71139000
CY2021 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1954000
CY2019 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1246000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114481000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91080000
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72385000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20329000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27092000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16151000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
34000000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
35000000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1837000
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1146000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
330000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
62000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1507000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1084000
CY2021 us-gaap Depreciation
Depreciation
285000
CY2020 us-gaap Depreciation
Depreciation
75000
CY2019 us-gaap Depreciation
Depreciation
45000
CY2021Q2 meip Accrued Preclinical And Clinical Costs
AccruedPreclinicalAndClinicalCosts
4004000
CY2020Q2 meip Accrued Preclinical And Clinical Costs
AccruedPreclinicalAndClinicalCosts
2343000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3513000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3410000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
813000
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
226000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
72000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
111000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8402000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6090000
CY2021 meip Unsold Securities Shares And Warrants Under Agreement
UnsoldSecuritiesSharesAndWarrantsUnderAgreement
107500000
CY2021Q2 meip Aggregate Value Of Securities Available Under Agreement
AggregateValueOfSecuritiesAvailableUnderAgreement
175700000
CY2021Q2 meip Shelf Registration Statement Value
ShelfRegistrationStatementValue
100000
CY2021Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
22400000
CY2020Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
40500000
CY2021 meip Number Of Warrants Exercised
NumberOfWarrantsExercised
2617
CY2021 meip Number Of Shares Issued On Warrant Exercise
NumberOfSharesIssuedOnWarrantExercise
964
CY2020 meip Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2021Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
226100000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote per share
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
100000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
10245000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
6801000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
6562000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11252976
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.81
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6201300
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.39
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
141907
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.34
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
643827
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.43
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
16668542
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.01
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4739572
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8416964
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.78
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M6D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3954990
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
5777907
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.05
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6201300
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.30
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
587890
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
2.31
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
3139739
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
2.04
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
8251578
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.23
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
8300000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.005
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.027
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.801
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.741
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.825
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.30
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.64
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.78
CY2020Q3 meip Initial Recognition Of Operating Lease Right Of Use Asset
InitialRecognitionOfOperatingLeaseRightOfUseAsset
8700000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8700000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7370000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1507000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
692000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
685000
CY2021 meip Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
983000
CY2020 meip Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
0
CY2019 meip Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
0
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8689000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1519000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1565000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1612000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1168000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1710000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
3121000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10695000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2397000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
8298000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
928000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
8298000
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y9M18D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0750
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-46016000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-16819000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-50567000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-46016000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-16819000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-10619000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-9663000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3532000
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
99000
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-9000
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-86000
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2021 meip Effective Income Tax Rate Reconciliation Tax Expensebenefit Warrant Liability Amount
EffectiveIncomeTaxRateReconciliationTaxExpensebenefitWarrantLiabilityAmount
-3806000
CY2021 meip Effective Income Tax Rate Reconciliation Tax Expensebenefit Warrant Liability Percentage
EffectiveIncomeTaxRateReconciliationTaxExpensebenefitWarrantLiabilityPercentage
0.08
CY2020 meip Effective Income Tax Rate Reconciliation Tax Expensebenefit Warrant Liability Amount
EffectiveIncomeTaxRateReconciliationTaxExpensebenefitWarrantLiabilityAmount
4803000
CY2020 meip Effective Income Tax Rate Reconciliation Tax Expensebenefit Warrant Liability Percentage
EffectiveIncomeTaxRateReconciliationTaxExpensebenefitWarrantLiabilityPercentage
-0.10
CY2019 meip Effective Income Tax Rate Reconciliation Tax Expensebenefit Warrant Liability Amount
EffectiveIncomeTaxRateReconciliationTaxExpensebenefitWarrantLiabilityAmount
-5803000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-50567000
CY2019 meip Effective Income Tax Rate Reconciliation Tax Expensebenefit Warrant Liability Percentage
EffectiveIncomeTaxRateReconciliationTaxExpensebenefitWarrantLiabilityPercentage
0.35
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
6000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-138000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.01
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
12481000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.25
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4230000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.09
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
9082000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.54
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1847000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.04
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
638000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
478000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.03
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021Q2 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
18339000
CY2020Q2 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
17325000
CY2021Q2 meip Deferred Tax Assets Property Plant And Equipment And Intangible Assets
DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets
15924000
CY2020Q2 meip Deferred Tax Assets Property Plant And Equipment And Intangible Assets
DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets
18832000
CY2021Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4182000
CY2020Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3834000
CY2021Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16104000
CY2020Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2214000
CY2021Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
727000
CY2020Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
709000
CY2021Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
22000
CY2020Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
20000
CY2021Q2 meip Deferred Tax Assets Right Of Use Assets
DeferredTaxAssetsRightOfUseAssets
-1633000
CY2020Q2 meip Deferred Tax Assets Right Of Use Assets
DeferredTaxAssetsRightOfUseAssets
0
CY2021Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1742000
CY2020Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0
CY2021Q2 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
1000
CY2020Q2 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
0
CY2021Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
55408000
CY2020Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42934000
CY2021Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
55408000
CY2020Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42934000
CY2021Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
70800000
CY2021Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
17700000
CY2021 meip Taxable Income Percentage
TaxableIncomePercentage
0.80

Files In Submission

Name View Source Status
0000950170-21-001655-index-headers.html Edgar Link pending
0000950170-21-001655-index.html Edgar Link pending
0000950170-21-001655.txt Edgar Link pending
0000950170-21-001655-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img102213294_0.jpg Edgar Link pending
img102213294_1.jpg Edgar Link pending
img136429673_0.jpg Edgar Link pending
img137353194_0.jpg Edgar Link pending
meip-20210630.htm Edgar Link pending
meip-20210630.xsd Edgar Link pending
meip-20210630ex10_5.htm Edgar Link pending
meip-20210630ex10_6.htm Edgar Link pending
meip-20210630ex23_1.htm Edgar Link pending
meip-20210630ex31_1.htm Edgar Link pending
meip-20210630ex31_2.htm Edgar Link pending
meip-20210630ex32_1.htm Edgar Link pending
meip-20210630_cal.xml Edgar Link unprocessable
meip-20210630_def.xml Edgar Link unprocessable
meip-20210630_htm.xml Edgar Link completed
meip-20210630_lab.xml Edgar Link unprocessable
meip-20210630_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending